Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Harvard Business School
Dow
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR TAFINLAR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tafinlar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting GlaxoSmithKline Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting Novartis Pharmaceuticals Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗ Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2013-07-19 This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01940809 ↗ Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 1 2013-08-28 This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether ipilimumab works better with or without dabrafenib, trametinib, and/or nivolumab in treating melanoma.
NCT01947023 ↗ Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 1 2013-08-29 This phase I trial studies the side effects and best dose of lapatinib when given together with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery and has not responded to previous treatment (refractory). Dabrafenib and lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02143050 ↗ Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting James Graham Brown Cancer Center Phase 1/Phase 2 2014-09-01 The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.
NCT02143050 ↗ Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting University of Louisville Phase 1/Phase 2 2014-09-01 The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafinlar

Condition Name

Condition Name for Tafinlar
Intervention Trials
Melanoma 13
Metastatic Melanoma 7
Stage IIIC Cutaneous Melanoma AJCC v7 6
Stage IV Cutaneous Melanoma AJCC v6 and v7 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tafinlar
Intervention Trials
Melanoma 22
Skin Neoplasms 9
Neoplasms 8
Glioma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tafinlar

Trials by Country

Trials by Country for Tafinlar
Location Trials
United States 234
Australia 7
Germany 5
United Kingdom 3
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tafinlar
Location Trials
Massachusetts 11
Texas 10
California 8
Pennsylvania 8
Arizona 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tafinlar

Clinical Trial Phase

Clinical Trial Phase for Tafinlar
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 17
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tafinlar
Clinical Trial Phase Trials
Recruiting 15
Active, not recruiting 12
Withdrawn 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tafinlar

Sponsor Name

Sponsor Name for Tafinlar
Sponsor Trials
National Cancer Institute (NCI) 15
Novartis 4
Novartis Pharmaceuticals 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tafinlar
Sponsor Trials
Other 41
Industry 30
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
AstraZeneca
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.